July 2019
Volume 60, Issue 9
Free
ARVO Annual Meeting Abstract  |   July 2019
Prognostication of uveal melanoma patients: are exosomes the solution?
Author Affiliations & Notes
  • Emine Kilic
    Dept of Ophthalmology, Erasmus Medical Center, Rotterdam, Netherlands
  • Kyra Smit
    Dept of Ophthalmology, Erasmus Medical Center, Rotterdam, Netherlands
  • Natasha van Poppelen
    Dept of Ophthalmology, Erasmus Medical Center, Rotterdam, Netherlands
  • Taran Lunavat
    . Krefting Research Centre, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden
  • Jolanda Vaarwater
    Dept of Ophthalmology, Erasmus Medical Center, Rotterdam, Netherlands
  • Su Chul Jang
    . Krefting Research Centre, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden
  • Robert M. Verdijk
    Dept of Ophthalmology, Erasmus Medical Center, Rotterdam, Netherlands
  • Jan Lötvall
    . Krefting Research Centre, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden
  • Annelies de Klein
    Clinical Genetics, Erasmus MC, Rotterdam, Netherlands
  • Footnotes
    Commercial Relationships   Emine Kilic, None; Kyra Smit, None; Natasha van Poppelen, None; Taran Lunavat, None; Jolanda Vaarwater, None; Su Chul Jang, None; Robert Verdijk, None; Jan Lötvall, None; Annelies de Klein, None
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 749. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Emine Kilic, Kyra Smit, Natasha van Poppelen, Taran Lunavat, Jolanda Vaarwater, Su Chul Jang, Robert M. Verdijk, Jan Lötvall, Annelies de Klein; Prognostication of uveal melanoma patients: are exosomes the solution?. Invest. Ophthalmol. Vis. Sci. 2019;60(9):749. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Uveal melanoma (UM) is the most common primary intraocular malignancy in adults. It is a highly aggressive cancer in which nearly 50% of patients die from liver metastasis. UM patients can be divided into 3 groups based on their genetic profile and disease free survival; the low metastatic risk, intermediate metastatic risk and high metastatic risk tumours. Since tumour tissue is not always available and biopsies are not without risk, it is important to develop a method that can identify high risk patients in a non-invasive manner. Exosomes are an excellent candidate for this application.

Methods : We isolated exosomes from conditioned cell culture medium from non-metastatic and metastatic UM cell lines by ultracentrifugation and an Optiprep density gradient. To confirm the presence of exosomes in our sample, we performed flow cytometry, electron microscopy and Nanosight Tracking Analysis. Subsequently we isolated and analysed the RNA and protein content of the UM exosomes by sequencing, qPCR and mass spectrometry, respectively.

Results : mRNA and cDNA sequencing of exosomal RNA identified UM-specific mutations in EIF1AX, SF3B1 and BAP1. Mass spectrometry analysis of the exosomal surface proteins, did not only identify exosomal markers such as CD81, CD9 and CD63 but also melanocyte-specific proteins such as Melan-A and GP100.

Conclusions : The expression of melanocyte-specific markers on the exosome surface might make it possible to enrich for UM exosomes from blood. Analyzing the genomic content of these exosomes allows us to determine the patients’ metastatic risk. These results highlight the potential of exosomes as non-invasive predictors of disease free survival in UM. Detecting UM-specific mutations in exosomal mRNA derived from plasma, will enable us to provide all UM patients with a prognosis and may also lead to future therapeutic targets.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×